Our assumption about the potential efficacy of this drugs' combination was reinforced by the fact that Forschner et al. indicated that EGFR amplification occur in around 30% of MM patients, while Gottesdiener detected—belonging to EGRF family—ERBB2 amplifications in 6% of MM.25, 26. The gene discussed is ERBB2; the disease is Miyoshi myopathy.